Clinical Research Directory
Browse clinical research sites, groups, and studies.
Phase II Trial to Modulate Intermediate Endpoint Biomarkers in Former and Current Smokers
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Summary
The purpose of this study is to find out if an investigational combination drug called Lovaza (made with fish oils)+Curcumin C3 Complex (made from a root called curcumin) can help reduce the size of lung nodules. Researchers also want to find out if the combination of Lovaza+Curcumin C3 Complex is safe and tolerable.
Official title: Phase II Trial of Investigational Agents to Modulate Intermediate Endpoint Biomarkers, Including Pulmonary Nodules, in Former and Current Smokers
Key Details
Gender
All
Age Range
55 Years - Any
Study Type
INTERVENTIONAL
Enrollment
19
Start Date
2019-06-05
Completion Date
2026-05
Last Updated
2026-02-27
Healthy Volunteers
Yes
Interventions
Curcumin C3 complex®
Groups A and B as outlined in study arm. Drug will be dispensed by investigational pharmacists and self-administered by the participants.
Lovaza®
Groups A and B as outlined in study arm. Drug will be dispensed by investigational pharmacists and self-administered by the participants.
Placebo
Groups B and Placebo as outlined in study arm. Drug will be dispensed by investigational pharmacists and self-administered by the participants.
Locations (1)
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, United States